The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation

On October 24, 2019, a marketing authorization valid through the European Union (EU) was issued for gilteritinib monotherapy for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an Fms‐like tyrosine kinase 3 (FLT3) mutation. Gilteritinib inhibits FLT3 receptor signali...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Tzogani, Kyriaki, Røshol, Hilde, Olsen, Helga Haugom, Aas, Ida B., Dalhus, Marianne Løiten, Håkonsen, Gro Dahlseng, Nilssen, Laila Sortvik, Lindberg, Vibeke, Økvist, Mats, Bolstad, Bjørg, Rogovska, Irēna, Karpova, Natalja, Enzmann, Harald, Gisselbrecht, Christian, Pignatti, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Regulatory Issues: EMA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356782/
https://ncbi.nlm.nih.gov/pubmed/32154636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0976
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados